Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03277729
Recruitment Status : Recruiting
First Posted : September 11, 2017
Last Update Posted : July 13, 2021
National Cancer Institute (NCI)
Mustang Bio
Information provided by (Responsible Party):
Fred Hutchinson Cancer Research Center

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : November 16, 2022
Estimated Study Completion Date : November 16, 2037